Rydex Biotechnology Fund Class C (RYCFX)

Fund Assets	123.77M
Expense Ratio	2.40%
Min. Investment	$2,500
Turnover	75.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 16, 2025

Previous Close	56.30
YTD Return	30.00%
1-Year Return	58.95%
5-Year Return	37.45%
52-Week Low	41.36
52-Week High	56.50
Beta (5Y)	0.68
Holdings	73
Inception Date	Mar 30, 2001

About RYCFX

Rydex Biotechnology Fund Class C is an open-end mutual fund focused on the biotechnology sector within the broader healthcare industry. Its primary objective is to achieve capital appreciation by investing primarily in companies involved in biotechnology, including firms engaged in research, development, and commercialization of innovative medical products and technologies. The fund holds a portfolio of approximately 78 securities, with a significant, though not exclusive, concentration in biotechnology firms, making it sensitive to developments and trends within the sector. The fund is team-managed and overseen by Security Investors, LLC, and it is designed for investors seeking exposure to the growth potential of biotechnology and related healthcare companies. It periodically distributes income and capital gains, with an expense ratio that reflects the specialized nature of the strategy. Rydex Biotechnology Fund Class C plays a distinctive role in the market by offering targeted access to a dynamic segment often associated with innovation in pharmaceuticals, medical devices, and genetic engineering, appealing to those interested in thematic sector investing.

• Fund Family: Rydex Funds
• Category: Health
• Performance Rating: Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: RYCFX
• Share Class: Class C
• Index: S&P 500 TR

Performance

RYCFX had a total return of 58.95% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.38%.

Equivalent Funds

These are funds that follow the same index from the other major fund companies.

Symbol	Provider	Name	Expense Ratio
FIKCX	Fidelity	Fidelity Advisor Health Care Z	0.56%
FSPHX	Fidelity	Fidelity Select Health Care Portfolio	0.62%
FIJYX	Fidelity	Fidelity Advisor Biotechnology Z	0.58%
FSHCX	Fidelity	Fidelity Select Health Care Services Portfolio	0.67%
FBTAX	Fidelity	Fidelity Advisor Biotechnology A	0.96%

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
RYOIX	Investor Class	1.40%
RYBOX	Class A	1.65%
RYOAX	Class H	1.65%

Top 10 Holdings

36.17% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	8.15%
Amgen Inc.	AMGN	5.04%
Gilead Sciences, Inc.	GILD	4.48%
Vertex Pharmaceuticals Incorporated	VRTX	4.31%
Regeneron Pharmaceuticals, Inc.	REGN	2.93%
Revolution Medicines, Inc.	RVMD	2.47%
Alnylam Pharmaceuticals, Inc.	ALNY	2.35%
BeOne Medicines AG	ONC	2.17%
Moderna, Inc.	MRNA	2.14%
Biogen Inc.	BIIB	2.12%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 16, 2025	$9.40578	Dec 16, 2025
Dec 12, 2024	$9.42277	Dec 12, 2024
Dec 20, 2022	$0.89943	Dec 20, 2022
Dec 8, 2021	$15.77303	Dec 8, 2021
Dec 9, 2020	$6.95038	Dec 9, 2020
Dec 10, 2019	$3.60206	Dec 10, 2019

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Aug 27, 2026

Data Sources Report a data error